Cargando…

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT

BACKGROUND: CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs. METHODS: Ninety patients with histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Serfling, Sebastian E., Lapa, Constantin, Dreher, Niklas, Hartrampf, Philipp E., Rowe, Steven P., Higuchi, Takahiro, Schirbel, Andreas, Weich, Alexander, Hahner, Stefanie, Fassnacht, Martin, Buck, Andreas K., Werner, Rudolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296404/
https://www.ncbi.nlm.nih.gov/pubmed/35312939
http://dx.doi.org/10.1007/s11307-022-01717-1
_version_ 1784750265638846464
author Serfling, Sebastian E.
Lapa, Constantin
Dreher, Niklas
Hartrampf, Philipp E.
Rowe, Steven P.
Higuchi, Takahiro
Schirbel, Andreas
Weich, Alexander
Hahner, Stefanie
Fassnacht, Martin
Buck, Andreas K.
Werner, Rudolf A.
author_facet Serfling, Sebastian E.
Lapa, Constantin
Dreher, Niklas
Hartrampf, Philipp E.
Rowe, Steven P.
Higuchi, Takahiro
Schirbel, Andreas
Weich, Alexander
Hahner, Stefanie
Fassnacht, Martin
Buck, Andreas K.
Werner, Rudolf A.
author_sort Serfling, Sebastian E.
collection PubMed
description BACKGROUND: CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs. METHODS: Ninety patients with histologically proven solid cancers underwent CXCR4-targeted [(68)Ga]Ga-PentixaFor PET/CT. Volumes of interest (VOIs) were placed in normal organs (heart, liver, spleen, bone marrow, and kidneys) and tumor lesions. Mean standardized uptake values (SUV(mean)) for normal organs were determined. For CXCR4-positive tumor burden, maximum SUV (SUV(max)), tumor volume (TV), and fractional tumor activity (FTA, defined as SUV(mean) x TV), were calculated. We used a Spearman's rank correlation coefficient (ρ) to derive correlative indices between normal organ uptake and tumor burden. RESULTS: Median SUV(mean) in unaffected organs was 5.2 for the spleen (range, 2.44 – 10.55), 3.27 for the kidneys (range, 1.52 – 17.4), followed by bone marrow (1.76, range, 0.84 – 3.98), heart (1.66, range, 0.88 – 2.89), and liver (1.28, range, 0.73 – 2.45). No significant correlation between SUV(max) in tumor lesions (ρ ≤ 0.189, P ≥ 0.07), TV (ρ ≥ -0.204, P ≥ 0.06) or FTA (ρ ≥ -0.142, P ≥ 0.18) with the investigated organs was found. CONCLUSIONS: In patients with solid tumors imaged with [(68)Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged.
format Online
Article
Text
id pubmed-9296404
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92964042022-07-21 Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT Serfling, Sebastian E. Lapa, Constantin Dreher, Niklas Hartrampf, Philipp E. Rowe, Steven P. Higuchi, Takahiro Schirbel, Andreas Weich, Alexander Hahner, Stefanie Fassnacht, Martin Buck, Andreas K. Werner, Rudolf A. Mol Imaging Biol Research Article BACKGROUND: CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs. METHODS: Ninety patients with histologically proven solid cancers underwent CXCR4-targeted [(68)Ga]Ga-PentixaFor PET/CT. Volumes of interest (VOIs) were placed in normal organs (heart, liver, spleen, bone marrow, and kidneys) and tumor lesions. Mean standardized uptake values (SUV(mean)) for normal organs were determined. For CXCR4-positive tumor burden, maximum SUV (SUV(max)), tumor volume (TV), and fractional tumor activity (FTA, defined as SUV(mean) x TV), were calculated. We used a Spearman's rank correlation coefficient (ρ) to derive correlative indices between normal organ uptake and tumor burden. RESULTS: Median SUV(mean) in unaffected organs was 5.2 for the spleen (range, 2.44 – 10.55), 3.27 for the kidneys (range, 1.52 – 17.4), followed by bone marrow (1.76, range, 0.84 – 3.98), heart (1.66, range, 0.88 – 2.89), and liver (1.28, range, 0.73 – 2.45). No significant correlation between SUV(max) in tumor lesions (ρ ≤ 0.189, P ≥ 0.07), TV (ρ ≥ -0.204, P ≥ 0.06) or FTA (ρ ≥ -0.142, P ≥ 0.18) with the investigated organs was found. CONCLUSIONS: In patients with solid tumors imaged with [(68)Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged. Springer International Publishing 2022-03-21 2022 /pmc/articles/PMC9296404/ /pubmed/35312939 http://dx.doi.org/10.1007/s11307-022-01717-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Serfling, Sebastian E.
Lapa, Constantin
Dreher, Niklas
Hartrampf, Philipp E.
Rowe, Steven P.
Higuchi, Takahiro
Schirbel, Andreas
Weich, Alexander
Hahner, Stefanie
Fassnacht, Martin
Buck, Andreas K.
Werner, Rudolf A.
Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
title Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
title_full Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
title_fullStr Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
title_full_unstemmed Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
title_short Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
title_sort impact of tumor burden on normal organ distribution in patients imaged with cxcr4-targeted [(68)ga]ga-pentixafor pet/ct
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296404/
https://www.ncbi.nlm.nih.gov/pubmed/35312939
http://dx.doi.org/10.1007/s11307-022-01717-1
work_keys_str_mv AT serflingsebastiane impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT lapaconstantin impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT dreherniklas impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT hartrampfphilippe impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT rowestevenp impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT higuchitakahiro impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT schirbelandreas impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT weichalexander impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT hahnerstefanie impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT fassnachtmartin impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT buckandreask impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct
AT wernerrudolfa impactoftumorburdenonnormalorgandistributioninpatientsimagedwithcxcr4targeted68gagapentixaforpetct